Skip to main content
LFCR logo

LFCR · Lifecore Biomedical, Inc. De

Track LFCR — free
$6.37 -0.03 (-0.47%)
Market Cap
$242.60M
Shares
37.91M
Volume · Nov 19 186.33K Avg daily vol (3M) 405.18K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.40 Open$6.40 Day$6.39–6.41 52W close$3.66–8.82 Avg vol 30d394K Short int1.7M · 4.5% of shares · 3.5d Short vol19% Last earningsAug 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Nov 23, 2026 Est · unconfirmed · in 1 wks

Latest documents

2026
Nov 13
Proxy statement DEFM14A
Stockholders to vote on $6.28-per-share merger on December 23

Lifecore Biomedical stockholders will vote on December 23, 2026 on a merger that would make the company a wholly owned subsidiary, paying $6.28 per common share in cash plus one contingent value right.

Read from the first part of this long document
4 source passages
Lifecore Biomedical, Inc. (“Company,” “Lifecore,” “we,” “us” and “our”) on December 23, 2026, at 10:00 a.m. Central Time (unless the special meeting is adjourned or postponed), in a virtual-only meeting format. The merger agreement provides that, among other things, on the terms and subject to the conditions of the merger agreement, Merger Sub will merge with and into the Company (the “merger”), with the Company surviving the merger as a wholly owned subsidiary of Parent. At the effective time, each share of common stock issued and outstanding immediately prior to the effective time, excluding any excluded shares, will be canceled and cease to exist and be converted into the right to receive $6.28 per share in cash, without interest (the “base consideration”) plus one (1) contingent value right per share (each, a “CVR”) (collectively, the “common stock merger consideration”). Open the document at this passage
Nov 5
Proxy statement DEFA14A
Antitrust waiting period ends early for merger

The Department of Justice and Federal Trade Commission granted early termination of the HSR Act waiting period effective November 4, 2026, satisfying a closing condition for Lifecore Biomedical’s merger. Stockholder approval and other conditions remain.

2 source passages
On November 4, 2026, the Department of Justice and the Federal Trade Commission granted early termination of the waiting period under the HSR Act effective as of November 4, 2026, satisfying the HSR Act condition to the closing of the Merger. The Merger remains subject to the remaining closing conditions and approvals, including the adoption of the Merger Agreement by Company stockholders at a special meeting. Open the document at this passage
Nov 5
Current report 8-K Events of Nov 4
Merger clears antitrust waiting period on November 4, 2026

Lifecore Biomedical’s merger cleared the antitrust waiting period on November 4, 2026, satisfying a closing condition; the transaction still requires stockholder approval and other remaining conditions.

Other events
3 source passages
As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. (“Parent”) and Hazel Merger Sub, Inc. (“Merger Sub”) providing for the merger of Merger Sub with and into the Company (the “Merger”), with the Company surviving as a wholly owned subsidiary of Parent. On November 4, 2026, the Department of Justice and the Federal Trade Commission granted early termination of the waiting period under the HSR Act effective as of November 4, 2026, satisfying the HSR Act condition to the closing of the Merger. The Merger remains subject to the remaining closing conditions and approvals, including the adoption of the Merger Agreement by Company stockholders at a special meeting. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2027 Q1, ended Sep 30
Merger agreement amid revenue decline and preferred redemption

Lifecore entered a merger agreement with affiliates of Webster Equity Partners on September 27, 2026 as nine-month revenue fell $23.0 million. All 50,187 Series A Preferred Stock shares were tendered for redemption, scheduled for December 28, 2026.

Revenue $25.32M ▼ 18.6% Net loss $40.08M Diluted EPS -$1.08
Read from the MD&A section
4 source passages
Lifecore generates revenues from two activities within a single, integrated segment: CDMO and HA manufacturing. On September 27, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with affiliates of Webster Equity Partners. The decrease of $23.0 million in revenues was primarily due to a $20.3 million decrease in CDMO revenue, which was primarily from $15.6 million of overall lower sales volumes, $2.3 million of lower pricing primarily due to a price concession to a customer in exchange for a multi-year extension of its commercial agreement, a $1.7 million take-or-pay arrangement in the prior period, and $0.8 million of lower development revenue. As of September 30, 2026, the Company had received notices of redemption for all 50,187 shares of Series A Preferred Stock. Pursuant to the terms of the Series A Preferred Stock, the redemption date and payment of the redemption price for all shares of the Series A Preferred Stock would occur on December 28, 2026. Open the document at this passage
Nov 4
Current report 8-K
Revenue falls 18.6%; net loss widens to $40.1 million

Lifecore Biomedical reported third-quarter revenue of $25.3 million, down 18.6%, and net loss of $40.1 million for the period ended September 30, 2026. Nine-month revenue was $82.7 million, down 21.8%; liquidity totaled approximately $38.0 million.

Financial results
5 source passages
Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the third quarter and nine months ended September 30, 2026. Revenues for the third quarter of 2026 were $25.3 million, a decrease of $5.8 million, or 18.6% compared to $31.1 million for the prior year quarter ended September 30, 2025. Net loss for the third quarter of 2026 was $40.1 million or $1.08 loss per diluted share, as compared to net loss of $10.0 million or $0.29 loss per diluted share, for the prior year quarter ended September 30, 2025. Revenues for the nine months ended September 30, 2026, were $82.7 million, a decrease of $23.0 million, or 21.8% compared to $105.7 million for the nine months ended September 30, 2025. Ended the third quarter of 2026 with approximately $38.0 million in liquidity, including cash of $23.0 million and revolving credit availability of $15.0 million. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-18.6%
Year over year
Operating margin
-13.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$137.93M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.2%
Year over year · more shares
Price change (1Y)
-15.8%
Trailing year
Short interest
4.5%
Latest settlement · 3.5 days to cover
View all 125 metrics

AI Brief

Q1 FY26 earnings call · May 6, 2026
Q1 FY26

TL;DR. Q1 revenue, gross profit and adjusted EBITDA deteriorated year over year, with much of the previously disclosed headwind front-loaded into the first half. However, management reaffirmed 2026 revenue and adjusted EBITDA guidance, signed three commercial site transfers expected to contribute in 2028, reduced expenses, improved liquidity and entered Q2 with all orders in and revenue visibility of roughly 32 to 34 million.

Bullish
  • + Management reaffirmed 2026 revenue guidance of $120 to $125 million and adjusted EBITDA guidance of $20.5 to $25 million.
  • + The three newly signed commercial site-transfer programs are expected to generate mid-seven-figure opportunities and commercial revenue in 2028. new
  • + SG&A and R&D expenses declined for a sixth consecutive quarter, bringing cumulative reductions since late 2024 to almost $8 million. new
  • + All second-quarter orders were in, providing visibility to revenue in the roughly 32 to 34 million range. new
  • + LifeCore is preparing for its largest customer's commercial demand to double beginning in 2027. new
  • + Liquidity improved to approximately $38 million. new
Bearish
  • − First-quarter revenue fell 34%, declining 12 million to $23.2 million from $35.2 million. new
  • − Gross profit fell 5.4 million to $4.5 million from $9.8 million. new
  • − Adjusted EBITDA fell 4.7 million to $1 million from $5.7 million. new
  • − A Q1 revenue miss was shifted into Q2. new
  • − Approximately 50% of the previously disclosed headwind affected Q1, with roughly 80% expected to flow through first-half results. new
  • − Management's 2026 guidance includes a net loss of $35.4 to $30.9 million. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Mentioned in fund letters

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Bullish Fundamentals Weak Quant / Vol High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +19%
above
Price vs 50-day avg +8%
above
RSI (14) 61
neutral
MACD trend Negative
52-week position 53%
mid-range
Momentum
relative strength
Strong
1-month return 0%
trailing
6-month return +27%
trailing
YTD return −22%
this year
Relative strength +31%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +15 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.54% of shares out · ▼ -4.5% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
106 holders — near 3-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Weak
Revenue growth +6%
Y/Y
Gross margin 7%
contracting
EPS growth −485%
Y/Y
Free cash flow $-13.6M
Buyback $3.8M
authorized
Balance sheet $122.2M
net debt
Quant / Vol
risk profile
High
Volatility 80%
annualized · 1-yr
Max drawdown −59%
past year
ATR 1.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 1 of last 3
Latest guidance · from the 8-K filed Aug 5, 2026
calendar year 2026
Revenue $120M – $125M
Adjusted EBITDA Non-GAAP $20.5M – $25M
2029 Long-Term
Revenue $212M – $225M
by year-end 2029
Adjusted EBITDA margin Non-GAAP at least 25%
Previous outlook earlier release · from the 8-K filed Aug 7, 2025

Still-open targets the latest release did not restate under the same label.

Revenue · remainder of calendar year 2025 (an approximately seven-month tr $74M – $76M
Adjusted EBITDA · remainder of calendar year 2025 (an approximately seven-month tr $12M – $14M
Net (loss) · Seven-month period May 26, 2025 to December 31, 2025 $-19,800 – $-17,800
Prior guidance period ended · from the 8-K filed Aug 5, 2026
Projected 2026 Adj. EBITDA · 2026 $20.5M – $25M
Guided vs delivered · last 3 settled
Revenue full year fiscal 2024
guided $125M – $130M
$128.26M In line
Revenue FY23
guided $122M – $126M
$103.27M Miss −16.7%
Consolidated Revenues full year fiscal 2022
guided $179M – $185M
$111.27M Miss −38.9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+19% Bullish
Price vs 50-day avg
+8% Bullish
RSI (14)
61 Neutral
MACD trend
Negative Bearish
52-week position
53% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +15 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.54% of shares out · ▼ -4.5% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
106 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $6 · 53% Range high $9
vs 200-day avg +19% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $9.6M six months ended June 30, 2026 —
Early-Mid Stage Projects 22 as of June 2026 —
Employees 400 Lifecore at a Glance —
Free cash flow non-GAAP $880K Six months ended June 30, 2026 —
Late Stage Projects 16 as of June 2026 —
liquidity $38.8M second quarter of 2026 —
New business wins in the last twelve months 13 last twelve months —
Sq. Ft. Facility 248,000 Lifecore at a Glance —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LFCR
Lifecore Biomedical, Inc. De
this stock
$242.60M -21.8% +6.4% — 4.5%
TAK
Takeda Pharmaceutical Co Ltd
$67.96B +36.4% — — 0.1%
GALDY
Galderma Group AG
$51.90B +7.4% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$49.28B +35.3% +4.3% 96.0 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
106
% held
67.1%
Net QoQ
+34.5K sh
Top holder
WYNNEFIELD CAPITAL INC
Held Float
View
Held by Funds
Fund positions
95
View
Short & Settlement
Short Interest Falling
Shares short
1.7M
Days to cover
3.5d
Change
-80.9K sh
View
Short Volume
Short vol %
19%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
687
Value
$4.4K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
57.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$557.6M
Net income (FY)
$-38.7M
EPS diluted
$-1.27
View
Buybacks
Authorized
$3.8M
View
Filings
SEC Filings
Latest
DEFM14A
Filed
Nov 13, 2026
This year
20

Lifecore Biomedical stockholders will vote on December 23, 2026 on a merger that would make the company a wholly owned subsidiary, paying $6.28 per common share in cash plus one contingent value right.

View
Proposed Sales
Value
$71.7K
Shares
10.0K
Filed
Nov 20, 2024
View
Earnings & Events
Webcasts
Last webcast
Aug 5, 2026
View
Investor Relations
Latest news
Lifecore Biomedical to Participat…
Published
Oct 7, 2026
View

Performance

5D 20D 120D MTD YTD
LFCR +0.0% +0.5% +27.5% +0.0% -21.8%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +3.9% +6.0% +31.0% +3.4% -28.8%

Capital returns

Buyback program · as of Feb 26, 2023
Authorized
$3.80M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1005286 CUSIP 514766104 13F (30d) 127 filings 101 filers Visit website Investor relations